Inovio Pharma Stock
Inovio Pharma Stock
Our community is currently high on Inovio Pharma with 4 Buy predictions and 2 Sell predictions.
With a target price of 7 € there is potential for a 1215.79% increase which would mean more than doubling the current price of 0.53 € for Inovio Pharma.
Our community identified positive and negative aspects for Inovio Pharma stock for the coming years. 1 users see the criterium "Business model" as a plus for the Inovio Pharma stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Inovio Pharma in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Inovio Pharma vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Inovio Pharma | - | - | - | - | - | - | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $5.00 price target on the stock.
Show more
Ratings data for INO provided by MarketBeat